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Maternal antibodies (MatAbs) protect offspring
from infections but limit their responses to vaccina-
tion. The mechanisms of this inhibition are still
debated. Using murine early-life immunization
modelsmimicking the condition prevailing in humans,
we observed the induction of CD4-T, T follicular help-
er, and germinal center (GC) B cell responses even
when early-life antibody responses were abrogated
by MatAbs. GC B cells induced in the presence of
MatAbs form GC structures and exhibit canonical
GC changes in gene expression but fail to differen-
tiate into plasma cells and/or memory B cells in a
MatAb titer-dependent manner. Furthermore, GC B
cells elicited in the presence or absence of MatAbs
use different VH and Vk genes and show differences
in genes associatedwith B cell differentiation and iso-
type switching. Thus, MatAbs do not prevent B cell
activation but control the output of the GC reaction
both quantitatively and qualitatively, shaping the anti-
gen-specific B cell repertoire.INTRODUCTION
The toll of infectious diseases is at its highest during the first
year of life (Bhutta and Black, 2013), a period of vulnerability
that may be mitigated by the presence of antibodies of
maternal origin. Seroprotection may be achieved or enhanced
by maternal immunization inducing or increasing maternal anti-
body (MatAb) titers and, thus, their subsequent transplacental
transfer to the offspring (Edwards, 2015). The positive effect
of this intervention is demonstrated by the reduction in infant
hospitalization and death following maternal immunization
against tetanus, influenza, and pertussis (Benowitz et al.,Cell Re
This is an open access article under the CC BY-N2010; Kachikis and Englund, 2016), whereas novel maternal
vaccines against respiratory syncytial virus (RSV) (Mazur
et al., 2018) and group B Streptococcus (Lin et al., 2018) are
in advanced clinical development.
Numerous studies, including recent ones (Jones et al., 2014),
have reported dampening or inhibition of antibody responses in
infants of immunized mothers (Kurikka et al., 1995; Englund
et al., 1995; Borra`s et al., 2012; Maertens et al., 2017), and it
is therefore essential to assess the long-term effect of maternal
immunization on the early-life immune system (Giles et al.,
2018). Maternal immunization against S. pneumoniae was
even associated with increased risk of otitis media in the first
6 months of life despite infant immunization at 2 and 4 months
(Daly et al., 2014).
The mechanisms of inhibition of responses to immunization
by MatAbs are still debated. Twenty years ago, total CD4+
T cell responses were described as being largely unaffected
(Siegrist et al., 1998a, 1998b) even when antibody responses
were fully inhibited by MatAbs. It was postulated that B cell re-
sponses were inhibited mainly by (1) antigen neutralization (live
replicating vaccines); (2) epitope masking preventing antigen
binding and, thus, infant B cell priming (as in antibody feedback
regulation studies) (Br€uggemann and Rajewsky, 1982; Heyman
and Wigzell, 1984); (3) active inhibition of infant B cell activation
by Fcg receptor IIB (FcgRIIB)-mediated signaling (Kim et al.,
2011; Edwards, 2015); and (4) clearance of MatAb-coated vac-
cine antigens through Fc-dependent phagocytosis (Siegrist,
2003).
In contrast to all of these hypotheses, we show here that even
high MatAb titers do not prevent neonatal B cell activation or
their differentiation in germinal center (GC) B cells following
vaccination but that they subsequently affect GC B cell differen-
tiation into plasma cells (PCs) and memory B cells (MBCs),
imposing significant differences in their VH and Vk gene usage.
Thus, MatAbs exert their influence on neonatal and infant B
cell responses both quantitatively and qualitatively by shaping
the GC output and the antigen-specific B cell repertoire.ports 28, 1773–1784, August 13, 2019 ª 2019 The Author(s). 1773
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. High Titers of Antigen-Specific
Maternal Antibodies Inhibit Neonatal Anti-
body Responses to Vaccination
(A) Schematic representation of the experimental
model. BALB/c females received two doses of HA/
MF59 intramuscularly (i.m.) on days 0 (prime) and
21 (boost). 3 weeks post-boost, vaccinated or
unimmunized (controls) females were mated with
C57BL/6J males to generate CB6F1 offspring.
(B) Kinetics of the waning of HA-specific IgG
maternal antibodies in naive CB6F1 pups fromHA/
MF59-immunized mothers; dots show values per
individual mouse, whereas red lines indicate
means. Data are from one representative experi-
ment.
(C and D) Neonates born to HA/MF59-immunized
(immune mother) or naive control mothers were
vaccinated at 1 week of age with HA/CAF01. Non-
immunized pups from immune mothers served as
a control group. Data are representative of at least
two independent experiments. Mann-Whitney U
test: *p < 0.05, **p < 0.01, ***p < 0.001.
(C) HA-specific IgG titers post immunization.
Values represent mean logarithmic titers (log10)
of at least six mice per group ± SEM. Statistics
show significant differences between HA/CAF01-
immunized pups from immune and naive mothers.
(D) Serum HA-specific IgG1b titers 4 weeks after
neonatal immunization (or in immune BALB/c
mothers). Dots show values per individual mouse,
whereas lines indicate means ± SEM; n = 4–7
mice/group.RESULTS
High Titers of Antigen-Specific Maternal Antibodies
Inhibit Neonatal and Infant Antibody Responses to
Vaccination
We developed a first model of MatAb transfer in which BALB/c
female mice (Igha) received two doses of a monovalent influenza
hemagglutinin (HA)-based vaccine adjuvanted with MF59 (HA/
MF59) to induce very high HA-specific immunoglobulin G (IgG)
titers (on average, 5.0 log10 3 weeks post-boost) and were sub-
sequently mated with C57BL/6J males (Ighb) to generate CB6F1
offspring expressing both Igha and Ighb antibodies (Figure 1A).
This allowed discriminating MatAbs from the antibodies gener-
ated by neonatal immunization. In the first 2 weeks of age, HA-
specific IgG titers were similarly high in the offspring as in their
mother (Figure 1B). In the offspring, MatAbs declined steadily
over time, persisting for up to 20 weeks after birth (Figure 1B).
To elicit strong neonatal responses to influenza HA, we used
the CAF01 adjuvant (Vono et al., 2018). Neonatal (1-week-old)
mice born to influenza-immune or -naive (control) mothers
received one dose of HA/CAF01 (or were left unimmunized as
controls), and HA-specific IgG titers were measured regularly
after immunization. High and sustained HA-specific antibody1774 Cell Reports 28, 1773–1784, August 13, 2019responses were detected in immunized neonates from naive
mothers (Figure 1C), as reported previously (Vono et al., 2018).
In contrast, active immunization did not induce antibody re-
sponses in the offspring of immune mothers; HA-specific IgG ti-
ters remained similar in HA/CAF01-vaccinated and naive control
pups from immunemothers (Figure 1C). Because HA/CAF01 pri-
marily induces IgG1 antibodies (Vono et al., 2018), we measured
HA-specific IgG1
b antibodies, which were only observed in pups
born to naivemothers (Figure 1D). Postponing immunization until
the age of 3 weeks (infant mice), when HA-specific IgG anti-
bodies were 5-fold lower (4.5 log10), was not yet sufficient to
elicit antibody responses to HA/CAF01 (Figure S1). This
confirmed that high levels of HA-specific MatAbs fully inhibited
early-life antibody responses to HA/CAF01.
Maternal Antibodies Do Not Affect Total CD4+ T Cell
Responses but Limit the Expansion of T Follicular Helper
(TFH) Cells
Total CD4+ T helper (Th) cell responses were reported as being
unaffected even in the presence of MatAb levels that completely
inhibited antibody responses (Siegrist et al., 1998a; Weeratna
et al., 2001; Crowe et al., 2001). Accordingly, HA/CAF01 immu-
nization induced similar HA-specific CD4+ T cell responses
Figure 2. Maternal Antibodies Do Not Affect Total CD4+ T Cell Re-
sponses but Limit the Expansion of TFH Cells
(A–D) 1-week-old CB6F1 mice born to HA/MF59-immunized or naive
mothers were vaccinated (or not) with a single dose of HA/CAF01.
Groups of neonates from naive mothers received HA/PBS as an additional
control.
(A) Spleens were harvested on day 12 after immunization, and HA-specific
CD4+ Th cells were reactivated in vitro with HA prior to intracellular
cytokine staining and flow cytometric analysis. The graph shows proportions
of CD4+CD44+ HA-specific cytokine-expressing T cells.
(B–D) On the indicated days after immunization, dLNs were harvested to
quantify TFH cells by flow cytometry. Shown are representative plots showing
CXCR5highPD-1high TFH cells among CD4
+ T cells (B). Graphs report the fre-
quencies (C) and the numbers (D) of TFH cells. Naive mice from both groups
served as controls.
(A, C, and D) Dots show values per individual mouse, whereas black lines
indicate means ± SEM; nR 3 mice/group. Data were pooled from at least two
independent experiments per time point. *p < 0.05, **p < 0.01, ***p < 0.001;
Mann-Whitney U test, all immunized groups significantly differed from naive
control mice (not shown in the graph) (A); one-way ANOVA (statistics betweenwith a predominant Th1/Th17 profile in pups of HA-immunized or
naive mothers. Frequencies of CD4+CD44+ T cells secreting
interleukin-2 (IL-2) but not other cytokines were even higher in
the offspring of immune mothers (Figure 2A).
TFH cells are specialized providers of T cell help to B cells and,
thus, essential for GC formation, affinity maturation, somatic mu-
tation, and development of high-affinity antibodies, PCs, and
MBCs (Crotty, 2011; Vinuesa et al., 2010). We thus measured
the frequencies and numbers of TFH cells in the draining lymph
nodes (dLNs) of immunized pups by flow cytometry. TFH cells
were defined as CD4+ CXCR5highPD-1high cells and gated as
shown in Figure 2B. As reported previously (Vono et al., 2018),
HA/CAF01 induced strong TFH cell responses in neonates of
naive mothers, with sustained frequencies up to day 22 (Fig-
ure 2C) and increasing numbers reaching a plateau on day 18 af-
ter immunization (Figure 2D). TFH cells were also induced in the
offspring of HA/MF59-immunized mothers but with different ki-
netics; TFH cell frequencies peaked on day 9 after immunization,
at similar frequencies as in control pups, but a decreasing trend
was observed over time (Figure 2C). TFH cell numbers did not in-
crease between days 9 and 22, remaining significantly lower in
pups of immunized than naive mothers (Figure 2D). The TFH
cell gated population highly expressed Bcl6, independent of
the presence of MatAbs (Figure S2). Administration of CAF01
without HA did not elicit TFH cell responses (Figure S3A).
Thus, although total CD4+ T cell responses were not affected
by the presence of high levels of MatAbs, they did not prevent in-
duction but limited the expansion of TFH cells.
High Levels of Maternal Antibodies Do Not Prevent
Induction of GC B Cells Post-Vaccination but Limit Their
Expansion
A single dose of HA/CAF01 induced potent GC B cell responses
in pups of naive mothers (Vono et al., 2018). Here we measured
B220+GL7+FAS+ GC B cells elicited by HA/CAF01 in the dLNs of
pups born to HA/MF59-immunized mothers (Figures 3A–3C).
Neonates immunized with HA/PBS or non-immunized served
as negative controls. As an additional specificity control, we veri-
fied that CAF01 administered without HA did not elicit GC B cell
responses (Figure S3B).
Unexpectedly, given the lack of antibody responses (Figures
1C and 1D), HA/CAF01 immunization did elicit GC B cells even
in pups born with high MatAb titers; GC B cells were detected
on day 9 in both groups, increasing until day 18. However, on
days 12 and 18, GC B cell frequencies (Figure 3B) and numbers
(Figure 3C) remained significantly lower in pups of immune
mothers than in pups of naive mothers. To confirm that these
GCB cells were organized in bona fideGC structures, we imaged
follicular B cells (IgD, green) and GC B cells (peanut agglutinin
[PNA], red) in sections of the dLNs. On days 12 (Figure 3D) and
18 (data not shown), well-organizedGC structures were observed
even in HA/CAF01-immunized pups born to immune mothers.
We next used biotin-labeled HA and fluorochrome-conjugated
streptavidin to estimate the proportion of HA-binding GC B cells,CAF01-adjuvanted and unadjuvanted groups from naive mothers are not
shown in the graph) (C and D).
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Figure 3. High Levels of Maternal Anti-
bodies Do Not Prevent Induction of GC B
Cells after Vaccination but Limit Their
Expansion
(A–D) Neonates born to HA/MF59-immunized or
naive mothers were vaccinated with HA/CAF01 or
left unimmunized. Groups of neonates born to
naive control mothers received HA/PBS as an
additional control.
(A–C) Draining LNs were harvested at the indi-
cated time points after immunization, and samples
were analyzed by flow cytometry. Representative
plots show the frequencies of GL7+FAS+ GC B
cells among B220+ B cells on day 18 after immu-
nization (A). Graphs report the frequencies (B) and
the numbers (C) of GC B cells over time for the
indicated conditions. Naivemice from both groups
served as negative controls. Dots show values per
individual mouse, whereas black lines indicate
means ± SEM. Data were pooled from at least two
independent experiments per time point. Statistics
between CAF01-adjuvanted and unadjuvanted
groups from naive mothers are not shown in the
graph. One-way ANOVA: *p < 0.05, ***p < 0.001.
(D) Representative sections of dLNs showing
immunohistochemical staining for IgD (green) and
the peanut agglutinin (PNA, red) GC marker; GC B
cells are IgDPNA+. n R 3 mice/group for all
experiments.which was technically challenging given the low number of GC B
cells following neonatal immunization. We observed an average
of 20% of HA-binding GCB cells independent of the presence or
absence of MatAbs (Figures 4A and 4B). However, we demon-
strated that, at the peak of GC responses (day 18 after immuni-
zation), total GC B cell frequencies correlate linearly with HA-
specific IgG antibody responses in neonates born to naive
mothers (Figure 4C).
To exclude the influence of other components transferred to
the offspring through maternal milk, we adoptively transferred
HA-immune serum in naive neonates 24 h prior to HA/CAF01 im-
munization. This generated the same observations as HA/CAF01
immunization in pups of immune mothers (data not shown).
Thus, even very high MatAb titers, which prevent induction of
any detectable antibody response, do not preclude induction of
GC B cells but limit their expansion.
High Titers of Maternal Antibodies Prevent GC B Cell
Differentiation toward PCs and MBCs
Within the GC reaction, B cells either die or further differentiate
into PCs or MBCs. We thus investigated the effect of MatAbs
on GC B cell differentiation toward PCs and MBCs.
Cells with the B220int/lowCXCR4+CD138+ PC phenotype were
quantitated by flow cytometry in dLNs on days 9, 12, 18, and 221776 Cell Reports 28, 1773–1784, August 13, 2019after HA/CAF01 neonatal vaccination
(Figures 5A and 5B; data not shown).
PCs were few, detectable only on day
18 after HA/CAF01 immunization in
pups of naive mothers (Figures 5A and
5B). PCs egress from lymph nodes(LNs), and homing to the bone marrow (BM) is critical for
their long-term survival, whereas other GC B cells develop
into MBCs. We thus measured PCs in the BM and spleen
(control) and MBCs in the spleen by enzyme-linked immunospot
(ELISpot) assay 10 weeks after HA/CAF01 immunization. We
observed low but consistent frequencies of PCs and MBCs in
immunized pups of control mothers. In contrast, neither PCs
nor MBCs were observed in the HA/CAF01-immunized offspring
of immune mothers (Figures 5C and 5D).
To obtain further evidence of B cell differentiation toward
MBCs, mice were boosted with HA/PBS 14 weeks after HA/
CAF01 priming, and their B cell recall responses were character-
ized. HA-specific IgG titers increased rapidly after boosting in the
offspring of naive but not of vaccinated mothers (Figure 5E).
Accordingly, high frequencies of PCs and MBCs were identified
in HA-boosted mice born to control mothers, whereas none
were observed in the HA-boosted offspring of immune mothers
(Figures 5F and 5G).
The unexpected observation that MatAbs drastically affect the
GC output, including MBC generation, prompted us to confirm
these findings using a different experimental model. Two-week-
old pups born to tetanus toxoid (TT)-immunized (or control)
mothers were immunized (or not) with TT/alum. In unimmunized
pups from immune mothers, TT-specific MatAbs persisted up to
Figure 4. Detection of HA-Specific GC B
Cells after a Single Injection of HA/CAF01
(A–C) Neonates born to HA/MF59-immunized or
naive mothers were vaccinated with HA/CAF01.
Draining LNs were harvested on day 18 after
immunization.
(A and B) The frequency of GL7+FAS+ GC B cells
that were able to bind biotinylated HA was as-
sessed by flow cytometry after addition of BV421-
conjugated streptavidin. Staining of cells with
streptavidin (SA) only in the absence of HA was
used to verify the specificity of the binding.
Representative plots show frequencies of HA-
specific GC B cells in mildly (1) and highly
responsive (2) mice (A). Graph shows frequencies
of HA-specific GCBcells (B). Dots show values per
individual mouse, whereas black lines indicate
means ± SEM n = 7 mice/group, Mann-Whitney U
test: *p < 0.05. Data are representative of at least
two independent experiments.
(C) Graph showing the correlation between total
GC B cell frequencies and HA-specific IgG anti-
body responses in neonates born to naive
mothers. n = 8 mice/group; data were pooled from
at least two independent experiments.24 weeks after birth (Figure S4A). Again, active immunization did
not elicit TT-specific IgG titers in pups from immunized mothers
(Figure S4B). TT/alum preferentially induced IgG1 antibodies
(Figure S4C), and IgG1
b antibodies were again only detected in
immunized pups from naive mothers, confirming total inhibition
of antibody responses by high levels of MatAbs (Figure S4D).
Vaccinated mice were boosted 12 weeks after prime with TT/
PBS to measure B cell recall responses. Again, TT-specific IgG ti-
ters did not increase after boosting in the offspring of vaccinated
mothers (Figure S4B), and TT-specific PCs and MBCs were only
observed in pups immunized in the absence of anti-TT MatAbs
(Figures S4E and S4F). Immunization with both TT and HA of
pups born to TT-immunized mothers elicited normal primary anti-
body, PC, and MBC responses to HA, contrasting the full inhibi-
tion of TT-specific responses and confirming the antigen speci-
ficity of the inhibition mediated by MatAbs (Figures S4G–S4I).
The Level of Maternal Antibodies Present at Priming
Determines GC B Cell Differentiation toward PCs
and MBCs
In human infants, MatAbs classically inhibit primary antibody
responses to vaccination (Markowitz et al., 1996). In most
cases, normal booster responses are elicited after MatAbs
have waned, suggesting little, if any, interference with MBC in-
duction (Bertley et al., 2004). However, there is clinical evidenceCell Repthat MatAbs depress both primary and
secondary antibody responses in young
infants vaccinated against measles (Njie-
Jobe et al., 2012).
To study the influence of lower MatAb
titers on B cell differentiation, we devel-
oped a secondmodel in which BALB/c fe-
males were immunized twice with HA/PBS instead of HA/MF59 before mating with C57BL/6J males.
CB6F1 neonates were then immunized with HA/CAF01 in the
presence of lower (3.8 log10 instead of 5 log10) anti-HA IgG
MatAb titers. Again, primary antibody responses were fully in-
hibited by MatAbs (Figure 6A), and HA-specific IgG1b antibodies
were not detected in these pups (data not shown). After HA/PBS
boosting, antibody titers increased in all primed mice, although
they remained significantly lower and of lower avidity in the
offspring of immune than control mothers (Figures 6A and 6B).
Accordingly, both PC (Figure 6C) and MBC (Figure 6D) re-
sponses were detected after boosting in immunized mice born
to immune mothers, at lower levels than in mice born to naive
mothers.
Thus, PC and MBC differentiation during GC responses may
be totally abrogated or reduced by various levels of MatAbs, ex-
plaining the influence of MatAb titers at the time of immunization
on the degree of inhibition of infant antibody responses (Marko-
witz et al., 1996).
Increasing the TT antigen dose also partially overcame the in-
hibition of antibody responses to vaccination in neonates born
with MatAbs (Figure S5), confirming that the MatAbs/antigen
dose ratio at the time of immunization determines the level of in-
hibition (Siegrist, 2003). Again, antibodies generated in pups
from TT-immune mothers were of lower avidity than the ones eli-
cited in control mice (Figure S5C).orts 28, 1773–1784, August 13, 2019 1777
Figure 5. High Titers of Maternal Antibodies Prevent GC B Cell Dif-
ferentiation toward PCs and MBCs
(A–G) CB6F1 neonates born to HA/MF59-immunized or naive mothers were
immunized with HA/CAF01 and boosted 14 weeks later with HA/PBS to
measure B cell recall responses. Neonates immunized with HA/PBS or un-
immunized served as controls.
(A and B) Cell suspensions from dLNs were analyzed by flow cytometry on day
18 after priming. Representative plots (A) and the graph (B) report the fre-
quencies of B220int/lowCXCR4+CD138+ PCs for the indicated conditions.
(C and D) Long-lived PCs (C) in the bone marrow (BM) and spleen and (D)
MBCs were measured 10 weeks after priming by ELISpot. Data are repre-
sentative of at least two independent experiments. n = 3–8 mice/group. *p <
0.05, **p < 0.01, ***p < 0.001.
(E) Total IgG titers were assessed at regular intervals. Values represent mean
logarithmic titers (log10) of at least six mice per group ± SEM. Statistics show
significant differences between HA/CAF01-immunized pups of immune and
naive mothers.
(F and G) Long-lived PCs (F) and MBCs (G) 3 weeks after boosting. Dots show
values per individual mouse, whereas black lines indicate means ± SEM.
Data were pooled from at least two independent experiments (B, E, F, and G);
Student’s t test (B) or Mann-Whitney U test (C–G).
1778 Cell Reports 28, 1773–1784, August 13, 2019High Titers of Maternal Antibodies Do Not Affect the GC
B Cell Signature Induced by HA/CAF01 in Neonates but
Interfere With Post-GC B Cell Differentiation
We next used genome-wide transcriptomics to characterize the
influence of MatAbs on GC responses elicited by HA/CAF01 in
neonates. Neonates born to HA/MF59-immunized or naive
mothers were vaccinated with HA/CAF01, and their dLNs were
collected 18 days later to isolate CD19+B220+GL7+FAS+ GC B
cells and control CD19+B220+ GL7negFASneg non-GC B cells
by flow cytometry cell sorting, according to the gates depicted
in Figure 7A. Gene expression analysis was performed by RNA
sequencing. We generated a multi-dimensional scaling plot to
obtain quantitative estimates of similarity among groups; GC B
cells adopted a unique activation and transcriptional state and
nicely separated from the rest of the B cells (Figure S6A).
Next we identified the differentially expressed genes (DEGs),
defined as those with a significant change in expression (adjusted
p < 0.05 false discovery rate [FDR]) in GC versus non-GC B cells.
Volcano plots illustrate the numbers of significantly downregu-
lated (blue dots) and upregulated (red dots) DEGs in neonates
born to naive (Figure S6B) or immune mothers (Figure S6C).
Changes reported as being relevant to GC B cell biology in adults
(Klein et al., 2003; De Silva and Klein, 2015) were observed in ne-
onates, regardless of whether HA/CAF01 immunization was per-
formed in the presence or absence of MatAbs. The heatmaps
illustrate the expression levels of selected GC-related genes,
grouped in main categories: cell cycle-related genes, GC-associ-
ated surface molecules, transcription factors, apoptosis-related
genes, and miscellaneous, with the latter including relevant but
unrelated genes (Figure 7B). The GC is a site of intense B cell pro-
liferation and cell death, and the transition of a naive to a GCB cell
is associated with dramatic changes in the expression of genes
related to cell proliferation and apoptosis (Klein et al., 2003).
Accordingly, proliferation-associated genes (e.g., the CDC and
CCN genes) and pro-apoptotic genes (e.g., Fas and Casp3)
were highly expressed in GC B cells, whereas the levels of Bcl2
and Nlrp10, negative regulators of apoptosis, were lower
compared with non-GC B cells. Other key changes associated
with the GC B cell state following immunization of adults were
observed in early life: upregulation of the Bcl6 and E2f1 transcrip-
tion factors, both important for GC formation. E2f1 induces Ezh2
expression, which controls G1-to-S phase transition of GCB cells
(Be´guelin et al., 2017). Downregulation ofGpr183 allowsGCBcell
migration to the follicle (Gatto et al., 2009). Downregulation of
S1pr1 and upregulation of S1pr2 promote confinement of B cells
in the GC (Green and Cyster, 2012).
Thus, the canonical changes reflecting the acquisition of a GC
B cell phenotype and state after HA/CAF01 neonatal immuniza-
tion are not affected by even high titers of MatAbs.
To better understand why GC B cells failed to differentiate into
MBCs and PCs in vaccinated pups of immune mothers, we next
compared GC B cells by RNA sequencing. Prior to antigen-
driven activation, resting B cells express IgM or IgD. Within the
GC, B cells proliferate at a high rate and undergo class switch
recombination (CSR) and somatic hypermutation (SHM). CSR
exchanges the Ig heavy-chain (Ighv) IgM constant region for
those of IgG, IgA, or IgE. The SHM of IgV genes drives affinity
maturation through selective expansion of cells with enhanced
Figure 6. The Level of Maternal Antibodies
Present at Priming Determines GC B Cell
Differentiation toward PCs and MBCs
(A–D) 1-week-old CB6F1 mice born to HA/PBS-
immunized or naive mothers were immunized with
HA/CAF01 and boosted 12 weeks later with HA/
PBS to measure B cell recall responses. Unim-
munized neonates from immune mothers served
as controls.
(A) Total IgG titers were measured over time after
prime (HA/CAF01) and boost (HA/PBS). Values
represent mean logarithmic titers (log10) ± SEM;
Mann-Whitney U test. Asterisks indicate signifi-
cant differences between HA/CAF01-immunized
pups from immunized and naive mothers: **p <
0.01, ***p < 0.001. # symbols indicate significant
differences between HA/CAF01-immunized and
naive pups from immune mothers: #p < 0.05, ##p <
0.01.
(B) The avidity of IgG antibodies was measured
15weeks after priming (3 weeks after HA boosting)
and is represented as percentages of eluted
HA-specific antibodies after treatment with
increasing concentrations of ammonium thiocya-
nate (NH4SCN).
(C and D) Long-lived PCs in the BM and spleen
(C) and MBCs (D) were measured 3 weeks
after boost by ELISpot. Dots show values per in-
dividual mouse, whereas black lines indicate
means ± SEM; n = 3–6 mice/group. Data are
representative of at least two independent exper-
iments. Mann-WhitneyU test; *p < 0.05, **p < 0.01.antigen binding (Victora and Nussenzweig, 2012), and high affin-
ity drives B cell differentiation toward PCs or MBCs (Kra¨utler
et al., 2017), ensuring the most productive GC output.
Only 39 DEGs distinguished GCB cells elicited in the presence
or absence of MatAbs (Figures 7C and 7D). Most were Ighv and
Igkv genes, indicating that GC B cells generated in presence or
absence of MatAbs use distinct B cell receptors (BCRs); i.e.,
they are responding to different epitopes (Figures 7C and 7D).
Significantly lower levels of the Ighm, Ighg2b, and Ighg2c
genes and increased levels of Ighg1were observed in GC B cells
from the offspring of naive mothers, in accordance with the
observed antibody responses in this group, predominantly
IgG1. Antigen-specific IgM responses were also inhibited in
the presence of high levels of MatAbs (Figures S7A and S7B).
Additional GC DEGs elicited in the presence of MatAbs included
higher levels of tbx21 (t-bet), whose restraint has been shown to
be important during an anti-influenza response (Piovesan et al.,
2017), and Cd72, a negative regulator of B cell responsiveness
(Parnes and Pan, 2000), whose suppression is necessary for B
cell differentiation. Lower levels of Nr4a1 (Nur77) and Fosb
were also observed; Nr4a1 regulates B cell survival and activa-
tion (Mayer et al., 2017), whereas Fos genes encode leucineCell Repzipper proteins that contribute to the
AP-1 transcription factor complex (Arguni
et al., 2006), which positively regulates
terminal differentiation of activated B
cells. Lower levels of Slpi, which plays arole in regulating the activation of nuclear factor kB (NF-kB)
and inflammatory responses (Mulligan et al., 2000), of Osgin1
and Capn11, which regulate apoptosis, and of the Cystm1
gene, which encodes a protein of the innate immune system-
related pathways, all concur to limit B cell differentiation within
GC B cells elicited in the presence of MatAbs.
Thus, high MatAb titers do not block B cell priming, as consid-
ered previously. They shape GC B cell differentiation, and, thus,
limit the generation of PCs andMBCs in aMatAb titer-dependent
manner. Major differences in Ighv and Igkv gene usage indicate
that GC B cells elicited in the presence of MatAbs express
distinct BCRs; i.e., they bind to distinct epitopes. This could be
explained by the masking of immunodominant epitopes by
MatAbs and the subsequent restriction of early-life B cell re-
sponses to non-immunodominant epitopes failing to drive the
affinity-dependent terminal TFH cell/GC B cell differentiation.
DISCUSSION
Although infectious diseases remain a major cause of death in
early life (Kollmann et al., 2017), many vaccines are not licensed
or require several doses to elicit protection under 6 months oforts 28, 1773–1784, August 13, 2019 1779
Figure 7. High Titers ofMaternal Antibodies DoNot Affect the GCBCell Signature Induced by HA/CAF01 in Neonates but Interfere with Post-
GC B Cell Differentiation
(A–D) 1-week-old CB6F1 mice born to HA/MF59-immunized or naive mothers were vaccinated with HA/CAF01.
(A) 18 days later, the two inguinal dLNs from 8 pups per group were collected and pooled to isolate sufficient numbers of highly pure (99%) CD19+B220+GL7+FAS+
GC B cells (GC) and control CD19+B220+ GL7negFASneg non-GC B cells (indicated as B) by flow cytometry cell sorting according to the illustrated gates.
(B) Transcriptomic studies were performed by RNA sequencing (RNA-seq). Heatmaps illustrate the expression levels of selected canonical GC genes in log2
(1+ reads per kilobase per million reads [RPKM]). Results include 3 independent pools of 8 mice per group.
(C) Volcano plot illustrating the numbers of significantly downregulated (blue dots) and upregulated (red dots) genes in GC B cells elicited in the presence
compared with the absence of MatAbs.
(D) Tables reporting significantly DEGs in GC B cells elicited in the presence compared with the absence of MatAbs, including gene name, log2 fold change (FC),
and p values.
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age. Protection against early-life infections like neonatal tetanus,
pertussis, or influenza may thus be best achieved by maternal
immunization and transplacental transfer of MatAbs. However,
MatAb titers decline with age, reaching titers insufficient for se-
roprotection while still interfering with infant antigen-specific
vaccine responses, generating a transient window of increased
vulnerability to infections.
The current concept is that immunization in the presence of
MatAbs essentially leaves CD4+ T cells unaffected but prevents
B cell activation and, thus, antibody responses (Siegrist, 2003).
Using several neonatal/infant immunization models, we show
here (1) that although CD4+ T effector cell responses remain
intact, TFH cells prematurely decline and (2) that even high titers
of MatAbs do not prevent B cell activation, GC B cell differentia-
tion, and the constitution of bona fide GC responses to neonatal
immunization. However, MatAbs drastically modulate the GC
output by reducing or preventing the generation of PCs and
MBCs in a MatAb- and antigen dose-dependent manner.
MatAbs exert their strongest influence on GC B cell differenti-
ation into antibody-secreting PCs; inhibition of antibody re-
sponses is exerted even at low MatAb titers (Figure 6A; unpub-
lished data), as observed in human infants (Edwards, 2015).
PC generation predominates late in the GC reaction (Weisel
et al., 2016), during which B cells do not undergo PC differentia-
tion stochastically; only GC B cells that have acquired a high af-
finity for the immunizing antigen through successive rounds of
differentiation between dark and light zones successfully form
PCs (Phan et al., 2006). This affinity maturation process requires
continuous TFH/B cell interactions within the GC (Zhang et al.,
2016). The normal induction but premature decline of TFH cell re-
sponses observed in the vaccinated offspring of immune
mothers (Figures 2B–2D) is direct evidence showing that MatAbs
influence the late phase of the GC reaction, limiting PC
generation.
At low or intermediate titers, MatAbs do not prevent the induc-
tion of MBCs, which may be rapidly recalled by a booster dose
given after MatAbs waning. MBCs develop early after immuniza-
tion (Weisel et al., 2016), at a stage during which we observed
normal numbers of TFH cells, presuming effective TFH/B cell in-
teractions within the GC. This condition prevails in human infants
for most infant vaccines (Bertley et al., 2004). Because microbial
exposure also reactivates MBCs and triggers their differentiation
into antibody-secreting PCs, their preserved induction/differen-
tiation may contribute to limit the increased vulnerability induced
by the presence of MatAbs. High MatAb titers, however, prevent
the induction of MBCs, inhibiting anamnestic responses even to
late boosters. Thus, MatAbs shape the GC output, interfering
first with PC and, subsequently, even with MBC differentiation
depending on their level at the time of neonatal/infant
immunization.
In addition to these quantitative effects, we observed a pro-
found qualitative influence of MatAbs on the early-life B cell dif-
ferentiation process. GC B cells elicited by neonatal HA/CAF01
immunization in the presence or absence of MatAbs had similar
phenotype and transcriptional profiles, indicating that MatAbs
do not block the development of canonical GC B cells. However,
although HA/CAF01 mainly induces IgG1 antibodies, a signifi-
cantly higher level of Ighm gene expression was observed inGC B cells elicited in presence of MatAbs, revealing limitations
in the CSR, which exchanges the Ig heavy-chain constant region
from that encoding IgM to that of IgG1. Furthermore, MatAbs eli-
cited a drastic influence on Ighv and Igkv gene usage, indicating
that B cells that differentiate into GC B cells in the presence or
absence of MatAbs express distinct BCRs; i.e., they bind to
distinct epitopes of vaccine antigens.
Previous studies revealed that adjuvants influence the immune
hierarchy of the immune response (Khurana et al., 2010).
Because we used two distinct vaccine adjuvants for mothers
(MF59) and pups (CAF01), the full inhibition of primary antibody,
PC, and even MBC responses was unexpected. However, we
cannot exclude a similar epitope specificity of antibodies elicited
byMF59- andCAF01-adjuvanted HA vaccines, enablingMatAbs
elicited by HA/MF59 to efficiently mask the immunodominant
epitopes recognized by the neonatal B cells induced by HA/
CAF01.
GC B cell clones acquiring increased affinity for antigen via
SHM are preferentially retained and selectively expanded (Vic-
tora and Nussenzweig, 2012; Jacob et al., 1991; Berek et al.,
1991), and only high-affinity B cells undergo CSR. Altogether,
the observations that GC B cells elicited in presence of MatAbs
were fewer, preferably expressed IgM, used distinct Ighv/Igkv
genes than GC B cells of control pups, and failed to differentiate
into PCs all suggest that MatAbs impair the affinity maturation
process; high-avidity MatAbs (Figures S7C and S7D) binding
to immunodominant epitopes may force binding of early-life B
cells to non-immunodominant epitopes. These are of lower affin-
ity, limiting their recruitment into the GC and reducing their
chance of surviving through the GC selection and PC differenti-
ation processes (Phan et al., 2006).
This hypothesis is supported by the observation that antibody
responses generated in the offspring of immune mothers, when
observed, are of lower avidity than in control mice (Figures 6B
and S5C). Direct evidence of this phenomenon is difficult to
obtain, given the paucity of epitope-specific GC B cells elicited
early in life, but our experimental findings all concur with the
conclusion that MatAbs affect epitope selection by infant B cells.
Epitope masking by MatAbs preventing infant B cell recogni-
tion is not a new hypothesis (Getahun and Heyman, 2009;
Niewiesk, 2014) and is supported by numerous experiments on
antibody feedback regulation (Br€uggemann and Rajewsky,
1982; Heyman and Wigzell, 1984; Bergstro¨m et al., 2017). Our
observations do not exclude a role for steric hindrance or for
BCR and FcgRIIB cross-linking blocking activation of some spe-
cific B cells (Karlsson et al., 2001; Sinclair et al., 1968). However,
they demonstrate that successful activation and differentiation
of neonatal and infant B cells into GC B cells do occur, even in
the presence of very high titers ofMatAbs, which essentially con-
trol the B cell fate within the GC and modulate the B cell reper-
toire in early life.
Beyond their academic interest, these observations have clin-
ical consequences. First, they indicate that clinical trials
comparing vaccine responses in infants of immunized or natu-
rally exposed versus non-immunized naive mothers should not
only assess the short-term effect but also the long-term influ-
ence of MatAbs; the influence on MBC generation and the
potential shift of infant B cell responses from immunodominantCell Reports 28, 1773–1784, August 13, 2019 1781
to non-immunodominant epitopes are still unknown. Next, they
prompt for the evaluation of immunization strategies maximizing
the protective efficacy of maternal immunization while mini-
mizing their inhibitory influence on infant B cell responses. This
might be achieved by postponing immunization of infants of
immunized mothers or providing additional/booster doses at
an age at which MatAbs have declined below the interfering
threshold. To some extent, this strategy is already empirically
used to ensure sufficient antibody responses (i.e., sufficient B
cell activation and PC differentiation) to current infant vaccines.
Alternatives include planning for a sufficiently high antigen
dose to be included in novel infant vaccines when maternal im-
munization is being considered; for example, against RSV. The
use of distinct vaccines in mothers and infants, possibly recruit-
ing distinct B cells into the immunodominant response, is
another attractive hypothesis. Last, it appears wise not to aim
to induce higher antibody titers in the mother than required for
child protection; using adjuvanted influenza, tetanus, or
pertussis vaccines in pregnant women should not be consid-
ered, given the demonstrated efficacy of non-adjuvanted vac-
cines inducing lower MatAb titers.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
BALB/c OlaHsd females and C57BL/6J OlaHsd males were purchased from Envigo (Horst, the Netherlands) and were crossed to
produce F1 CB6F1mice, both female andmale neonatal mice were used in the experiments. Mice were bred in pathogen-free animal
facilities in accordance with local guidelines. All experiments were approved by the Geneva veterinary office and conducted under
relevant Swiss and European guidelines.
METHODS DETAILS
Antigens, Adjuvants, and Immunization
We used a monovalent purified subunit influenza HA vaccine from H1N1 A/California/7/2009.
In the Influenza models, groups of 5 to 8 BALB/c OlaHsd females were immunized intramuscularly (i.m.) with HA (1 mg) mixed 1:1
(v/v) with MF59 (5% squalene, 0.5% Tween 80, and 0.5% Span 85 in citrate buffer [v/v]) (Novartis Vaccines) or with PBS, twice (day
0 and 21) prior to breeding.
Groups of 5 to 8 CB6F1 neonates (1 week-old) were immunized subcutaneously (s. c.) with HA (1 mg) in PBS or CAF01 (250 mgDDA/
50 mg TDB, Statens Serum Institut, Copenhagen, Denmark). Groups of neonates received CAF01 only as additional control.
In the tetanus toxoidmodel, BALB/c femaleswere immunized as abovewith 1/10 of a human dose of Infanrix (diphtheria-tetanus-
acellular pertussis (DTPa) on aluminum hydroxide, GlaxoSmithKline, Rixensart, Belgium). Groups of 5 to 8 CB6F1 pups were immu-
nized i.m. at 2 weeks of age with the indicated doses (Lf 0.025 or Lf 0.05) of tetanus toxoid (TT, Sanofi Pasteur, Lyon, France)
adsorbed to aluminum hydroxide (alum; 0.5 mg per mouse; Sanofi Pasteur). For experiments with TT-HA, groups of 3 to 5 CB6F1
pups were immunized i.m. at 2 weeks of age with both TT (Lf 0.025) and HA (1 mg) adsorbed to aluminum hydroxide (0.5 mg per
mouse).
For experiments of adoptive transfer, HA-specific hyperimmune serum (4.6 log10 IgG titers), generated in adult mice, was trans-
ferred (100 ml; intraperitoneal injection (IP)) in neonatal mice 24h prior to immunization with HA/CAF01.
Enzyme-Linked Immunosorbent Assay (ELISA)
Titration of Ag-specific total IgG and IgG1 titers was performed by ELISA on individual serum samples as previously described
(Mastelic Gavillet et al., 2015; Pihlgren et al., 2003). IgG1b titers were measured similarly, except that a biotin mouse anti-mouse
IgG1b antibody was used followed by streptavidin-HRP (both from BD Biosciences). IgM antibodies were measured similarly by
using a goat anti-mouse IgM antibody, HRP conjugate (ThermoFischer). Plates were coated with the same antigen (HA or TT)
used for immunization.
Enzyme-Linked Immunospot (ELISpot) Assay
HA-specific PCs were quantified by direct ex vivo ELISpot assay using 96-well multiscreen HA nitrocellulose filtration plates
(Millipore) coated with 50 mL of HA (4 mg/ml) in PBS, the same HA protein used for immunization. As positive control for total IgG-
secreting cells, 2 wells per plate were coated with a goat anti-mouse IgG (Invitrogen). The plates were incubated overnight at
4C, washed twice in PBS, and blocked with RPMI (GIBCO) plus 10% (v/v) Fetal Calf Serum (FCS; Bioconcept). The plates were
washed with PBS and cell suspensions were added at an initial number of 4x106 (bone-marrow) or 2x106 (spleen), followed by
1:2 serial dilutions in RPMI/ 10% (v/v) FCS.
The plates were incubated at 37C, 5%CO2 for 5 h prior to washing with PBS containing 0.1% (v/v) Tween (PBS-T). 100 mL of goat
anti-mouse IgG- HRP conjugated antibody (Invitrogen) diluted 1:1000 in PBS-T containing 1% (v/v) FCS was added and the plates
were incubated overnight at 4C. Plates were first washedwith PBS-T and thenwith PBS. Detection was performed by adding 100 mL
of 3-amino-9-ethylcarbazole substrate buffer for 30 min in the dark until spots appeared. The reaction was stopped by thorough
washing with cold tap water and air-dried. Spots were counted by eye under the microscope.
MBCs were detected using a modification of the PC ELISpot. In brief, 2x107 splenocytes were transferred in cell culture flask T25
(Nunc) together with 107 irradiated (1200 rad) naive congenic splenocytes and rested overnight. Cells were stimulated for 5 days with
a combination of R848 (0.5 mg/ml; Chemdea) and IL-2 (5 ng/ml; Peprotech), harvested, washed with RPMI medium and counted. Cell
suspensions were added to 96-wells multiscreen HA nitrocellulose filtration plates coatedwith influenza HA at an initial number of 107
cells, followed by eight 2-fold serial dilutions. The ELISpot assay was then performed as described above.
TT-specific PCs and MBCs were quantified similarly, except that plates were coated with 50 mL of TT (9.48 Lf/ml) in PBS.
Avidity Assay
Avidity was measured by an ELISA elution assay as the overall strength of binding between antibody and antigen, using plates incu-
bated for 15 min with increasing concentration of ammonium thiocyanate (NH4SCN) from 0 to 1.5 M in the HA model and from 0 to
3 M in the TT model, according to a well-established method (Macdonald et al., 1988). Antibody avidity was defined as the amount
(percentage) of antibody eluted for each increment of NH4SCN concentration.Cell Reports 28, 1773–1784.e1–e5, August 13, 2019 e3
Restimulation of HA-Specific CD4+ T Cells
Groups of 5 – 8mice were sacrificed at day 12 after immunization and spleens were collected to assess the frequency and phenotype
of HA-specific CD4+CD44+ T cells.
Intracellular cytokine production was assessed on 4x106 splenocytes/well in the presence of anti-CD28, anti-CD49d (both 1 mg/ml,
BD Pharmigen), and HA protein (1 mg/ml). Unstimulated or anti-CD3 (1 mg/ml; BD PharMingen) treated cells were used as negative
and positive controls, respectively.
Cells were cultured overnight prior to adding Brefeldin A (BFA, 5 mg/ml, Sigma-Aldrich) for the last 4 h. Cells were washed in PBS,
labeled with Live/Dead Fixable Aqua Stain Kit (ThermoFisher) and incubatedwith FcR blocking (Miltenyi Biotec). Surface staining was
performed with the following monoclonal antibodies: AF700 anti-CD3, PerCP-Cy5.5 anti-CD4 (both from BD PharMingen) and APC-
Cy7 anti-CD44 (Biolegend). Cells were fixed, permeabilized with the Fixation/Permeabilization Solution Kit (BD Cytofix/Cytoperm)
and stained intracellularly with APC anti- IFN-g, AF488 anti-IL-2 (both from BD PharMingen), eFluor 450 anti-IL-13 (Invitrogen),
A450 anti-IL-4 and PE anti-IL-17 (both from Biolegend). Samples were acquired on a Gallios cytometer (Beckman Coulter) and
the generated data analyzed using FlowJo Software (Tree Star).
Flow Cytometric Analysis of Lymph Node Cells
Cells from the two draining LNs of eachmousewere pooled and stainedwith fluorescently labeled antibodies to B220, andCD11b (all
from BD PharMingen), FAS (CD95), PD-1, Ter119, Ly-6G/Ly-6C, CXCR4 (all from Invitrogen), GL7, TCR-b, CD4, CD8, CD138, and
ICOS (all from BioLegend). CXCR5 staining was performed using purified anti-CXCR5 (BD PharMingen), followed by FITC anti-rat
IgG (Southern Biotech), and normal rat serum (Invitrogen). Intracellular Bcl6 staining was performed by using the Foxp3 transcription
factor buffer set (eBioscience) followed by an anti-Bcl6 antibody (BD PharMingen). The amount of live cells in samples was deter-
mined by using a Live/Dead viability kit (Thermo Fischer Scientific). To determine antigen specificity, cells were incubated with
20 mg/ml biotinylated HA (Sino Biological) and subsequently with BV421-conjugated streptavidin (BD PharMingen).
The stained cells were analyzed using a Gallios cytometer (Beckman Coulter) or a BD LSRFortessa and the generated data
analyzed using FlowJo Software (Tree Star).
Flow Cytometry Cell Sorting of Germinal Center B cells
The 2 inguinal draining LNs were collected 18 days after neonatal immunization, samples from each group were pooled and B cells
were enriched by using the EasySepMouse B Cell Isolation Kit (STEMCELL). Cells were stained with the following antibodies: AF488
anti- GL7, BV510 anti- B220 (BioLegend), PE-Cy7 anti- CD19 (BD PharMingen) PE anti- FAS, and APC anti- TCR b (Invitrogen).
B220+CD19+GL7+FAS+ GC B cells (purity R 99%) and B220+CD19+GL7negFASneg non-GC B cells were simultaneously isolated
from the enriched B cells by flow-cytometry cell sorting using a MoFlo Astrios flow cytometer (Beckman Coulter).
Immunohistochemistry
The draining LNs of immunized mice were stained and quantified as previously described for GC detection (Mastelic Gavillet et al.,
2015). Sections were visualized and photographedwith a Zeiss LSM700 confocal microscope (objective: 20x). Imageswere acquired
with Zeiss LSM image browser software (Zeiss).
RNA Sequencing
Total RNA was extracted from sorted cells using the RNeasy Mini Kit (QIAGEN, Germany) following the manufacturer’s instructions.
RNA concentration and integrity were assessed with a Bioanalyzer (Agilent Technologies). The SMARTer Ultra Low RNA kit
(Clontech) was used for reverse transcription and cDNA amplification according to the manufacturer’s specifications, starting
with 10 ng of total RNA as input. 200 pg of cDNA were used for library preparation using the Nextera XT kit from Illumina. Library
molarity and quality was assessed with the Qubit and Tapestation using a DNA High sensitivity chip (Agilent Technologies). Libraries
were pooled and loaded at 2 nM for clustering on a single-read Illumina flow cell. Reads of 50 bases were generated using the TruSeq
SBS chemistry on an Illumina HiSeq 4000 sequencer.
Three independent biological replicates were analyzed for each condition. Sequencing quality was checked and approved via the
FastQC software. FastQ readsweremapped to the ENSEMBL reference genome (GRCm38.89) using STAR (version 2.4.0j) with stan-
dard settings, except that any reads mapping to more than one location on the genome (ambiguous reads) were discarded (m = 1).
The RNA-seq data have been deposited to the Gene Expression Omnibus (GEO) under accession number GSE126015.
RNA-seq Data Analysis
Themodel used to quantify reads per gene considers all annotated exons of all annotated protein coding isoforms of a gene to create
a unique gene where the genomic region of all exons are considered coming from the same RNA molecule and merged together.
All reads overlapping the exons of each unique gene model were reported using featureCounts (version 1.4.6-p1). Gene expres-
sions were reported as raw counts and normalized in RPKM in order to filter out genes with low expression value (1 RPKM) before
calling for differentially expressed genes. Library size normalizations and differential gene expression calculations were performed
using the package edgeR (Robinson et al., 2010) designed for the R software. Only genes having a significant fold-change (Benja-
mini-Hochberg corrected p value < 0.05) were considered for the rest of the RNA-seq analysis.e4 Cell Reports 28, 1773–1784.e1–e5, August 13, 2019
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analyzed using Prism 7.0 (GraphPad Software) and presented as specified in figure legends. Difference between groups
was analyzed as described in figure legends. p values less than 0.05 were considered statistically significant.
DATA AND CODE AVAILABILITY
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